Search Tag: prostate cancer
2025 09 Nov
Prostate-specific membrane antigen PET/CT using fluorine-18 PSMA-1007 is being used to stage prostate cancer before treatment. Beyond image quality, the tracer’s practical features support routine deployment and may help visualise pelvic disease. A systematic review and metaanalysis pooled results from clinical studies that compared imaging directly...Read more
2025 25 Oct
Prostate-specific membrane antigen (PSMA) PET/CT has transformed prostate cancer assessment and is now embedded in guideline-recommended care. Yet the usefulness of advanced imaging depends on how consistently results are communicated. An analysis of consecutive external PSMA PET/CT reports received at a single tertiary centre highlights substantial...Read more
2025 16 Aug
Prostate cancer is one of the leading causes of cancer-related death and poses ongoing challenges for early detection. While prostate-specific antigen testing has shown an impact on mortality, it is hampered by low specificity and sensitivity. Men can be subjected to unnecessary procedures and anxiety due to false positives, while others with...Read more
2025 30 May
Affidea has acquired Uroviva, Switzerland’s top urology network, nearly doubling its size and expanding integrated oncology services. The move strengthens Affidea’s breast and prostate cancer pathways, combining diagnostics, treatment and monitoring. Uroviva’s expertise and advanced technologies will support a seamless, patient-centred care model...Read more
2025 30 May
Affidea has acquired Uroviva, Switzerland’s top urology network, nearly doubling its size and expanding integrated oncology services. The move strengthens Affidea’s breast and prostate cancer pathways, combining diagnostics, treatment and monitoring. Uroviva’s expertise and advanced technologies will support a seamless, patient-centred care model...Read more
2025 03 Apr
Strategic acquisition creates a leading oncology platform in Switzerland, with super-specialisation in breast and prostate cancer and an integrated care pathway Affidea Group, a leading pan-European provider of specialist healthcare services including cancer care, advanced diagnostic imaging and community-based polyclinics, today announced...Read more
2025 17 Mar
Focal therapy has emerged as a promising alternative to whole-gland treatments for prostate cancer, aiming to balance oncologic control with reduced adverse effects. Traditional methods, like radical prostatectomy and radiation therapy, provide well-documented long-term outcomes but often lead to significant morbidities such as urinary incontinence...Read more
2024 16 Nov
Radiomics has emerged as a transformative tool in prostate cancer diagnosis, using advanced image analysis to quantify tumour characteristics and improve diagnostic accuracy. For prostate cancer, early diagnosis is crucial, as it enhances treatment outcomes and overall survival rates. Radiomics extracts large volumes of quantitative data, or "features,"...Read more
2024 11 Jul
General Practitioners (GPs) in Bedfordshire, Luton, and Milton Keynes are adopting innovative strategies to prevent diseases, particularly focusing on prostate cancer and cardiovascular diseases. By leveraging the power of data through a method known as population health management, clinicians can identify individuals at higher risk, facilitating...Read more
2024 11 Jul
General Practitioners (GPs) in Bedfordshire, Luton, and Milton Keynes are adopting innovative strategies to prevent diseases, particularly focusing on prostate cancer and cardiovascular diseases. By leveraging the power of data through a method known as population health management, clinicians can identify individuals at higher risk, facilitating...Read more
2024 09 May
Radiation therapy (RT) is a common treatment for cancer, but it often leads to side effects like fatigue, stress, and sleep disturbance. Previous research suggests mindfulness can alleviate these symptoms, but traditional programs may be inaccessible to many patients. A recent study published in Global Advances in Integrative Medicine and Health...Read more
2018 23 Jan
Low dose rate (LDR) brachytherapy is commonly used for the treatment of prostate cancer. Although most patients who receive LDR brachytherapy for prostate cancer will be cured of their disease, biochemical recurrence occurs in 3%–13% of men undergoing monotherapy. New research demonstrates the efficacy of multiparametric magnetic resonance imaging...Read more